Oral Session 2-13C Hemophilia

[OS2-13C-6] Every 4 weeks (Q4W) emicizumab in persons with hemophilia A (PwHA): Results from HAVEN 4 study

Katsuyuki Fukutake¹, Steven Pipe², Victor Jimenez-Yuste³, Akira Ishiguro⁴, Takanori Teshima⁵, Amy Shapiro⁶, Nigel Key⁷, Maria Podolak-Dawidziak⁸, Cedric Hermans⁹, Peerlinck Kathelijne¹⁰, Michaela Lehle¹¹, Sammy Chebon¹¹, Agnes Portron¹¹, Nives Selak Bienz¹¹, Sayaka Nagami¹², Wataru Ohtsuka¹², Koichiro Yoneyama¹², Ryu Kasai¹², Gallia G. Levy¹³, Midori Shima¹⁴ (1.Labo-Med., Tokyo Med., Univ., Tokyo, Japan, 2.University of Michigan, C.S. Mott Children's Hospital, Ann Arbor, USA, 3.Hospital Universitario La Paz, Auto'noma University, Madrid, Spain, 4.Division of Hematol, NCCHD, Tokyo, Japan, 5.Hematol., Hokkaido Univ., Tokyo, Japan, 6.Indiana Hemophilia and Thrombosis Center, Indianapolis, USA, 7.University of N Carolina, Chapel Hill, North Carolina, USA, 8.Medical University Department of Hematology, Wroclaw, Poland, 9.UZ Leuven Gasthuisberg, Leuven, Belgium, 10.Cliniques Universitaires St-Luc, Brussels, Belgium, 11.F. Hoffmann-La Roche Ltd, Basel, Switzerland, 12.Chugai Pharmaceutical co., ltd., Tokyo, Japan, 13.Genentech Inc., South San Francisco; USA, 14.Pediatrics, Nara Med Univ. Kashihara, Japan)